Literature DB >> 8910634

K-ras point mutations in endometrial carcinoma: effect on outcome is dependent on age of patient.

K Ito1, K Watanabe, S Nasim, H Sasano, S Sato, A Yajima, S G Silverberg, C T Garrett.   

Abstract

Mutations involving the K-ras proto-oncogene are believed to play an important role in the mechanism of tumorigenesis for many human cancers and occur in 10-30% of endometrial carcinomas. In the present study 221 cases of endometrioid endometrial carcinoma obtained from Japanese patients with average follow-up of 41 months were examined for point mutations in codon 12 of K-ras through use of the polymerase chain reaction. In 103 cases lymph node dissection had been performed. K-ras mutations were significantly associated with the presence of lymph node metastases (P < 0.04). Since endometrial carcinoma in premenopausal women generally behaves less aggressively than tumors of similar histologic grade arising in postmenopausal patients, we evaluated the effect of K-ras mutation on outcome in patients stratified into three different age categories (<53 years, premenopausal; 54-59 years, perimenopausal; >60 years, postmenopausal). In the postmenopausal age group (>60 years), the presence of K-ras mutations was statistically significantly associated with patients who died or experienced recurrence (41.2% vs 13.0%; P < 0.03). This was related to a dramatic (greater than eightfold; P = 0.011) increase in the likelihood of adverse outcome between the premenopausal and postmenopausal states for patients whose tumors contained mutant K-ras. These findings point to a possible role for K-ras activation in the mechanism(s) responsible for more aggressive clinical behavior of endometrioid endometrial cancer that is observed in postmenopausal patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8910634     DOI: 10.1006/gyno.1996.0313

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  5 in total

Review 1.  Molecular cues on obesity signals, tumor markers and endometrial cancer.

Authors:  Danielle Daley-Brown; Gabriela M Oprea-Ilies; Regina Lee; Roland Pattillo; Ruben R Gonzalez-Perez
Journal:  Horm Mol Biol Clin Investig       Date:  2015-01

2.  Racial differences in oncogene mutations detected in early-stage low-grade endometrial cancers.

Authors:  Michele L Cote; Govindaraja Atikukke; Julie J Ruterbusch; Sara H Olson; Shawnita Sealy-Jefferson; Benjamin A Rybicki; Sharon Hensley Alford; Mohammad A Elshaikh; Arthur R Gaba; Daniel Schultz; Ramsi Haddad; Adnan R Munkarah; Rouba Ali-Fehmi
Journal:  Int J Gynecol Cancer       Date:  2012-10       Impact factor: 3.437

Review 3.  Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification.

Authors:  Sigurd F Lax
Journal:  Virchows Arch       Date:  2004-01-28       Impact factor: 4.064

4.  KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.

Authors:  E Birkeland; E Wik; S Mjøs; E A Hoivik; J Trovik; H M J Werner; K Kusonmano; K Petersen; M B Raeder; F Holst; A M Øyan; K-H Kalland; L A Akslen; R Simon; C Krakstad; H B Salvesen
Journal:  Br J Cancer       Date:  2012-10-25       Impact factor: 7.640

5.  The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905.

Authors:  Larissa J Lee; Elena Ratner; Mohamed Uduman; Kathryn Winter; Marta Boeke; Kathryn M Greven; Stephanie King; Thomas W Burke; Kelly Underhill; Harold Kim; Raleigh J Boulware; Herbert Yu; Vinita Parkash; Lingeng Lu; David Gaffney; Adam P Dicker; Joanne Weidhaas
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.